Luveltamab tazevibulin (STRO-002)
Folate receptor-alpha (FolRα) expressing ovarian cancer
Key Facts
About Sutro Biopharma
Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.
View full company profileAbout Sutro Biopharma
Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.
View full company profile